Clonal hematopoiesis and its emerging effects on cellular therapies

Area of Science:

• Hematology
• Oncology
• Immunology

Background:

• Somatic mutations accumulate in hematopoietic stem cells with age, leading to clonal expansion.
• Clonal hematopoiesis is linked to increased cardiovascular mortality, hematologic malignancies, and a pro-inflammatory state.
• It negatively impacts outcomes in patients with hematologic neoplasms and solid tumors.

Purpose of the Study:

• To review the implications of clonal hematopoiesis in treating hematologic malignancies using cell-based therapies.
• To discuss how clonal hematopoiesis affects autologous and allogeneic hematopoietic stem cell transplantation (HSCT).
• To analyze the impact of clonal hematopoiesis on chimeric antigen receptor (CAR) T-cell therapy.

Main Methods:

• Review of existing literature on clonal hematopoiesis and cell therapies.
• Analysis of mechanisms by which clonal hematopoiesis influences HSCT outcomes.
• Examination of how somatic mutations in effector or bystander cells affect CAR T-cell therapy efficacy.

Main Results:

• Transfer of clonally derived cells in HSCT can impact procedure outcomes.
• Pre-existing mutations in effector cells or clonal bystander cells can alter CAR T-cell therapy effectiveness.
• Clonal hematopoiesis presents complications for current cell therapeutic strategies.

Conclusions:

• Further registry studies and prospective trials are needed to clarify the role of donor- and recipient-derived clonal events in cell therapies.
• Novel insights into clonal hematopoiesis are crucial for refining therapeutic strategies in hematologic malignancies.
• Understanding clonal hematopoiesis is essential for optimizing outcomes in HSCT and CAR T-cell therapy.